[go: up one dir, main page]

SG11201508056XA - Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination - Google Patents

Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination

Info

Publication number
SG11201508056XA
SG11201508056XA SG11201508056XA SG11201508056XA SG11201508056XA SG 11201508056X A SG11201508056X A SG 11201508056XA SG 11201508056X A SG11201508056X A SG 11201508056XA SG 11201508056X A SG11201508056X A SG 11201508056XA SG 11201508056X A SG11201508056X A SG 11201508056XA
Authority
SG
Singapore
Prior art keywords
dysmyelination
treatment
methods
based disorders
promoting remyelination
Prior art date
Application number
SG11201508056XA
Inventor
Zhongyan Zhang
Mark G Mortenson
Original Assignee
Gr Intellectual Reserve Llc
Zhongyan Zhang
Mark G Mortenson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gr Intellectual Reserve Llc, Zhongyan Zhang, Mark G Mortenson filed Critical Gr Intellectual Reserve Llc
Publication of SG11201508056XA publication Critical patent/SG11201508056XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/242Gold; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0023Aggression treatment or altering
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Psychiatry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201508056XA 2013-05-08 2014-05-08 Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination SG11201508056XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361821040P 2013-05-08 2013-05-08
PCT/US2014/037280 WO2014182888A2 (en) 2013-05-08 2014-05-08 Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination

Publications (1)

Publication Number Publication Date
SG11201508056XA true SG11201508056XA (en) 2015-10-29

Family

ID=51867865

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201803748VA SG10201803748VA (en) 2013-05-08 2014-05-08 Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination
SG11201508056XA SG11201508056XA (en) 2013-05-08 2014-05-08 Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201803748VA SG10201803748VA (en) 2013-05-08 2014-05-08 Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination

Country Status (19)

Country Link
US (2) US20160143945A1 (en)
EP (1) EP2994146B8 (en)
JP (3) JP2016522192A (en)
KR (2) KR20210018955A (en)
CN (1) CN106385796A (en)
AU (1) AU2014262673B2 (en)
BR (1) BR112015026805B1 (en)
CA (1) CA2913205C (en)
DK (1) DK2994146T3 (en)
ES (1) ES2862705T3 (en)
HU (1) HUE054255T2 (en)
IL (1) IL242297B (en)
MX (1) MX382130B (en)
PH (1) PH12015502330B1 (en)
PT (1) PT2994146T (en)
RU (1) RU2686677C2 (en)
SG (2) SG10201803748VA (en)
SI (1) SI2994146T1 (en)
WO (1) WO2014182888A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821314A (en) * 2020-03-25 2020-10-27 巫远程 Eye drops for treating myopia and cataract and its preparing process
CN113092401B (en) * 2021-03-31 2022-09-13 重庆文理学院 Gas-sensitive analysis system for laboratory

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
CU23229A1 (en) * 2002-05-10 2007-09-26 Ct Ingenieria Genetica Biotech ANTH1 CHEMICAL ANTAGONIST
JP2004261885A (en) * 2003-02-18 2004-09-24 Japan Science & Technology Agency How to introduce functional materials into organic nanotubes
WO2005059952A2 (en) * 2003-07-28 2005-06-30 The Regents Of The University Of California Langmuir-blodgett nanostructure monolayers
US20050202406A1 (en) * 2003-11-25 2005-09-15 The Regents Of The University Of California Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems
US20060068026A1 (en) * 2004-08-11 2006-03-30 Hu Michael Z Thermal electrochemical synthesis method for production of stable colloids of "naked" metal nanocrystals
EP1825269A4 (en) * 2004-12-13 2012-06-06 Univ South Carolina IMPROVED RAMAN SPECTROSCOPY IN SURFACE USING FORMED GOLD NANOPARTICLES
US7588624B2 (en) * 2005-03-10 2009-09-15 Northwestern University Method of producing gold nanoprisms
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
WO2011006007A1 (en) * 2009-07-08 2011-01-13 Gr Intellectual Reserve, Llc Novel gold-based nanocrystals for medical treatments and electrochemical manufacturing processes therefor
WO2012036215A1 (en) * 2010-09-17 2012-03-22 Taniguchi Tadatsugu Inhibitor of hmgb protein-mediated immune response activation, and screening method
US8969077B2 (en) * 2010-11-05 2015-03-03 The Regents Of The University Of California Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord

Also Published As

Publication number Publication date
JP6985316B2 (en) 2021-12-22
PH12015502330B1 (en) 2020-10-02
DK2994146T3 (en) 2021-04-19
JP2019108387A (en) 2019-07-04
EP2994146A4 (en) 2017-02-08
JP2021165287A (en) 2021-10-14
KR20160007572A (en) 2016-01-20
NZ753043A (en) 2020-12-18
WO2014182888A2 (en) 2014-11-13
AU2014262673B2 (en) 2019-12-05
RU2015152248A (en) 2017-06-14
HUE054255T2 (en) 2021-08-30
PT2994146T (en) 2021-03-31
BR112015026805B1 (en) 2022-05-10
NZ712763A (en) 2020-12-18
BR112015026805A2 (en) 2017-10-31
PH12015502330A1 (en) 2016-02-22
EP2994146A2 (en) 2016-03-16
AU2014262673A1 (en) 2015-10-15
CA2913205C (en) 2023-01-03
US20160143945A1 (en) 2016-05-26
WO2014182888A3 (en) 2015-01-08
CN106385796A (en) 2017-02-08
KR102214256B1 (en) 2021-02-10
IL242297B (en) 2021-05-31
KR20210018955A (en) 2021-02-18
SG10201803748VA (en) 2018-06-28
MX382130B (en) 2025-03-13
EP2994146B8 (en) 2021-05-19
MX2015015467A (en) 2016-03-21
JP2016522192A (en) 2016-07-28
EP2994146B1 (en) 2021-03-03
RU2686677C2 (en) 2019-04-30
BR112015026805A8 (en) 2017-12-05
US20180228838A1 (en) 2018-08-16
SI2994146T1 (en) 2021-08-31
ES2862705T3 (en) 2021-10-07
CA2913205A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
IL278018A (en) Methods for treating or preventing ophthalmological conditions
IL273090B (en) Methods and compositions for the treatment of cancer
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
SG10201912275YA (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders
EP2991600A4 (en) Microclosures and related methods for skin treatment
IL239957A0 (en) Evaluation, assays and treatment of pkal-mediated disorders
IL237742A0 (en) Laquinimod and pridopidine for treating neurodegenerative disorders
SG11201510325XA (en) Methods for promoting neuronal development and/or health
PL2968478T3 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
IL276431A (en) Treating brain disorders and biomarkers related thereto
IL242297B (en) Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination
EP2968550A4 (en) Compositions and methods for treating angiogenesis-related disorders
HK40096540A (en) Evaluation and treatment of bradykinin-mediated disorders
GB201308665D0 (en) Device for the treatment of bone conditions
GB201321027D0 (en) Prescribe and treat